Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$62.2 - $84.4 $745,467 - $1.01 Million
-11,985 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$73.71 - $87.86 $87,125 - $103,850
1,182 Added 10.94%
11,985 $1.01 Million
Q3 2021

Nov 15, 2021

BUY
$77.92 - $102.4 $49,712 - $65,331
638 Added 6.28%
10,803 $974,000
Q2 2021

Aug 12, 2021

SELL
$92.19 - $115.71 $1 Million - $1.26 Million
-10,852 Reduced 51.63%
10,165 $969,000
Q1 2021

May 17, 2021

BUY
$106.9 - $167.73 $360,359 - $565,417
3,371 Added 19.1%
21,017 $2.39 Million
Q4 2020

Feb 19, 2021

BUY
$84.4 - $177.39 $1.49 Million - $3.13 Million
17,646 New
17,646 $2.44 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.96B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Aton Ra Partners Portfolio

Follow Aton Ra Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.